Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-08-15
S
Stacie M. Jones
High Impact
Professor
Also affiliated: University of North Carolina at Chapel Hill (2020); Scripps Research Institute (2004); University of Maryland, Baltimore (2006); Atrium Health Wake Forest Baptist (1996); Leeds General Infirmary (1997); Arkansas Children's Hospital (1991–2026); Children's Hospital of Philadelphia (1996); University of Nottingham (1988); Johns Hopkins University (1995–2024); Norwich University (1991); Guy's and St Thomas' NHS Foundation Trust (2022); University of Arkansas Medical Center (2003–2025); Johns Hopkins Medicine (1995); Centenary Institute (1980); Queen Elizabeth II Hospital (2002); University of California System (2023); University of Chicago (1996); London School of Hygiene & Tropical Medicine (1980); National Institute of Allergy and Infectious Diseases (2017–2024); Comer Children's Hospital (1996); Queen's Medical Centre (1988); Perry Point VA Medical Center (2006); Arkansas Children's Nutrition Center (2010); Johns Hopkins Hospital (2006); Arkansas Department of Agriculture (2002–2022); VA Maryland Health Care System (2006); Immune Deficiency Foundation (2006); Indiana University School of Medicine (2020); Wake Forest University (1996); American College of Emergency Physicians (2015); Icahn School of Medicine at Mount Sinai (2010)
Faculty Researcher
69 h-index
441 pubs
21,571 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Stacie M. Jones is a researcher at the University of Arkansas for Medical Sciences. Her work focuses on the treatment and understanding of food allergies, particularly in children. Jones has published extensively on various immunotherapy approaches, including oral immunotherapy (OIT) and epicutaneous immunotherapy, evaluating their efficacy, safety, and impact on quality of life.
Her research includes the investigation of pharmacologic treatments such as omalizumab for multiple food allergies. Jones also contributes to the development and refinement of diagnostic and grading tools, such as the CoFAR grading scale for systemic allergic reactions. Her scholarly output is substantial, with a high h-index of 69 and over 400 publications, indicating significant contributions to her field. She actively leads a research group and collaborates with colleagues at the University of Arkansas for Medical Sciences, including Amy M. Scurlock, Robbie Pesek, Brandi Whitaker, and Emily Seminara.
Metrics
- h-index: 69
- Publications: 441
- Citations: 21,571
Selected Publications
-
Treatment of Multifood Allergy With Omalizumab or Multiallergen Oral Immunotherapy (2026)
-
Implementation of early peanut introduction among providers in a southern US state (2026)
-
Dupilumab Failures in Pediatric and Adolescent Eosinophilic Esophagitis: A Retrospective Cohort Study (2026)
-
Management of Gastrointestinal Symptoms During Oral Immunotherapy: Guidance from OUtMATCH Investigators (2026)
-
Genetic Determinants of Peanut‐Specific <scp>IgG4</scp> Levels in the Context of Sustained Oral Peanut Exposure in the <scp>LEAP</scp> Study (2026)
-
Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergies (2025)
-
Introduction of allergenic foods after treatment with omalizumab (2025)
-
Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE (2025)
-
Multidisciplinary care in pediatric severe asthma: A comparative outcomes analysis (2025)
-
Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy (2024)
-
Omalizumab Implementation in Practice: Lessons Learned From the OUtMATCH Study (2024)
-
Impact of Atopic Status on Clinical Presentation and Treatment Response in Pediatric Patients With Eosinophilic Esophagitis (2024)
-
Enhanced Gut Microbiome Capacity for Amino Acid Metabolism is associated with Peanut Oral Immunotherapy Failure (2024)
-
Varying Doses of Epicutaneous Immunotherapy With Viaskin Milk vs Placebo in Children With Cow’s Milk Allergy (2024)
-
Long-Term Follow-up after IMPACT Peanut Oral Immunotherapy Clinical Trial (2024)
Collaboration Network
Top Collaborators
Edwin Kim
University of North Carolina at Chapel Hill (US)
11 shared publications
- Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy
- Updating the CoFAR Grading Scale for Systemic Allergic Reactions in Food Allergy
- Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)
- Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts
- Peanut-Specific IgG4 and IgA in Saliva Are Modulated by Peanut Oral Immunotherapy
Showing 5 of 11 shared publications
Scott H. Sicherer
Icahn School of Medicine at Mount Sinai (US)
11 shared publications
- Updating the CoFAR Grading Scale for Systemic Allergic Reactions in Food Allergy
- Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)
- Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts
- Mapping Sequential IgE-Binding Epitopes on Major and Minor Egg Allergens
- Allergen recognition by specific effector Th2 cells enables <scp>IL</scp> ‐2‐dependent activation of regulatory T‐cell responses in humans
Showing 5 of 11 shared publications
Brian P. Vickery
Children's Healthcare of Atlanta (US)
10 shared publications
- Open‐label follow‐on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy
- Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)
- Oral Immunotherapy for Peanut Allergy in Children 1 to Less Than 4 Years of Age
- Safety of peanut (Arachis hypogaea) allergen powder-dnfp in children and teenagers with peanut allergy: Pooled summary of phase 3 and extension trials
- Retail Food Equivalents for Post–Oral Immunotherapy Dosing in the Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen Oral Immunotherapy in Food-Allergic Children and Adults (OUtMATCH) Clinical Trial
Showing 5 of 10 shared publications
George Du Toit
Guy's and St Thomas' NHS Foundation Trust (GB)
10 shared publications
- Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy
- Open‐label follow‐on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy
- Oral Immunotherapy for Peanut Allergy in Children 1 to Less Than 4 Years of Age
- Safety of peanut (Arachis hypogaea) allergen powder-dnfp in children and teenagers with peanut allergy: Pooled summary of phase 3 and extension trials
- Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE
Showing 5 of 10 shared publications
Robert A. Wood
Johns Hopkins University (US)
10 shared publications
- Updating the CoFAR Grading Scale for Systemic Allergic Reactions in Food Allergy
- Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)
- Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts
- Mapping Sequential IgE-Binding Epitopes on Major and Minor Egg Allergens
- Allergen recognition by specific effector Th2 cells enables <scp>IL</scp> ‐2‐dependent activation of regulatory T‐cell responses in humans
Showing 5 of 10 shared publications
Wayne G. Shreffler
ENT and Allergy
10 shared publications
In database
- Updating the CoFAR Grading Scale for Systemic Allergic Reactions in Food Allergy
- Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)
- Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy
- Safety of peanut (Arachis hypogaea) allergen powder-dnfp in children and teenagers with peanut allergy: Pooled summary of phase 3 and extension trials
- Varying Doses of Epicutaneous Immunotherapy With Viaskin Milk vs Placebo in Children With Cow’s Milk Allergy
Showing 5 of 10 shared publications
A. Wesley Burks
University of North Carolina at Chapel Hill (US)
9 shared publications
- Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts
- Mapping Sequential IgE-Binding Epitopes on Major and Minor Egg Allergens
- Allergen recognition by specific effector Th2 cells enables <scp>IL</scp> ‐2‐dependent activation of regulatory T‐cell responses in humans
- Longitudinal dynamics of the gut microbiome and metabolome in peanut allergy development
- Peanut-Specific IgG4 and IgA in Saliva Are Modulated by Peanut Oral Immunotherapy
Showing 5 of 9 shared publications
R. Sharon Chinthrajah
Palo Alto University (US)
9 shared publications
- Updating the CoFAR Grading Scale for Systemic Allergic Reactions in Food Allergy
- Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)
- Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy
- Retail Food Equivalents for Post–Oral Immunotherapy Dosing in the Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen Oral Immunotherapy in Food-Allergic Children and Adults (OUtMATCH) Clinical Trial
- HLA-associated outcomes in peanut oral immunotherapy trials identify mechanistic and clinical determinants of therapeutic success
Showing 5 of 9 shared publications
Donald Y.M. Leung
National Jewish Health (US)
8 shared publications
- Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)
- Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts
- Mapping Sequential IgE-Binding Epitopes on Major and Minor Egg Allergens
- Allergen recognition by specific effector Th2 cells enables <scp>IL</scp> ‐2‐dependent activation of regulatory T‐cell responses in humans
- Longitudinal dynamics of the gut microbiome and metabolome in peanut allergy development
Showing 5 of 8 shared publications
Hugh A. Sampson
DBV Technologies (France) (FR)
7 shared publications
- Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts
- Mapping Sequential IgE-Binding Epitopes on Major and Minor Egg Allergens
- Allergen recognition by specific effector Th2 cells enables <scp>IL</scp> ‐2‐dependent activation of regulatory T‐cell responses in humans
- Longitudinal dynamics of the gut microbiome and metabolome in peanut allergy development
- Varying Doses of Epicutaneous Immunotherapy With Viaskin Milk vs Placebo in Children With Cow’s Milk Allergy
Showing 5 of 7 shared publications
Sayantani Sindher
Stanford University (US)
7 shared publications
- Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy
- Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy
- Varying Doses of Epicutaneous Immunotherapy With Viaskin Milk vs Placebo in Children With Cow’s Milk Allergy
- Introduction of allergenic foods after treatment with omalizumab
- Omalizumab Implementation in Practice: Lessons Learned From the OUtMATCH Study
Showing 5 of 7 shared publications
J. Andrew Bird
The University of Texas Southwestern Medical Center (US)
6 shared publications
- Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)
- Retail Food Equivalents for Post–Oral Immunotherapy Dosing in the Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen Oral Immunotherapy in Food-Allergic Children and Adults (OUtMATCH) Clinical Trial
- Varying Doses of Epicutaneous Immunotherapy With Viaskin Milk vs Placebo in Children With Cow’s Milk Allergy
- Omalizumab Implementation in Practice: Lessons Learned From the OUtMATCH Study
- Safety of Peanut (Arachis Hypogaea) Allergen Powder-dnfp in Children and Teenagers With Peanut Allergy: Pooled Analysis From Controlled and Open-Label Phase 3 Trials
Showing 5 of 6 shared publications
Daniel C. Adelman
University of California, San Francisco (US)
6 shared publications
- Updating the CoFAR Grading Scale for Systemic Allergic Reactions in Food Allergy
- Open‐label follow‐on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy
- Distinct trajectories distinguish antigen-specific T cells in peanut-allergic individuals undergoing oral immunotherapy
- Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy
- Safety of peanut (Arachis hypogaea) allergen powder-dnfp in children and teenagers with peanut allergy: Pooled summary of phase 3 and extension trials
Showing 5 of 6 shared publications
Julie Wang
Icahn School of Medicine at Mount Sinai (US)
6 shared publications
- Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy
- Allergen recognition by specific effector Th2 cells enables <scp>IL</scp> ‐2‐dependent activation of regulatory T‐cell responses in humans
- Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy
- Allergen recognition by specific effector Th2 cells enables IL-2-dependent activation of regulatory T cell responses in humans
- The SunBEAm birth cohort: Protocol design
Showing 5 of 6 shared publications
Thomas B. Casale
University of South Florida (US)
5 shared publications
- Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy
- Safety of peanut (Arachis hypogaea) allergen powder-dnfp in children and teenagers with peanut allergy: Pooled summary of phase 3 and extension trials
- Safety of Peanut (Arachis Hypogaea) Allergen Powder-dnfp in Children and Teenagers With Peanut Allergy: Pooled Analysis From Controlled and Open-Label Phase 3 Trials
- Corrections
- Reply
Similar Researchers
Based on overlapping research topics
Lindsey L. Morrison
University of Arkansas for Medical Sciences
Child and Adolescent Health
Pharmacological Effects and Toxicity Studies
Maternal and Perinatal Health Interventions
Nandini Mukherjee
University of Arkansas for Medical Sciences
Child and Adolescent Health
Immune Response and Inflammation
Pharmacological Effects and Toxicity Studies
Millicent Boakye
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Health and Medical Research Impacts
Substance Abuse Treatment and Outcomes
Madison Morris
University of Arkansas for Medical Sciences
Child and Adolescent Health
Health and Medical Research Impacts
Maternal and Perinatal Health Interventions
Stephen G. Jones
University of Arkansas for Medical Sciences
Child and Adolescent Health
Pharmacological Effects and Toxicity Studies
Health and Medical Research Impacts
Kanan K. Vyas
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Pharmacological Effects and Toxicity Studies
Disease Models, Animal